Rash in patients receiving ticlopidine after intracoronary stent placement.
As many as half of the approximately 400,000 patients who undergo nonsurgical coronary artery procedures every year receive an intracoronary stent. To prevent thrombus formation within the stent, antiplatelet treatment with ticlopidine and aspirin is administered. Ticlopidine is known to cause cutaneous adverse reactions in up to 5.1% of patients, with a 3.4% discontinuation rate. However, published studies of patients receiving the drug to prevent subacute thrombosis after intracoronary stent placement report a frequency of rash ranging from 0.8-1.6%. We hypothesized that the frequency of rash in this patient population is underreported, and conducted a retrospective chart review, collecting data on frequency and severity of rash, treatment required, patient demographics, and concomitant drugs that may predispose patients to rash. The frequency of rash was approximately 7% in this group of patients.
Department of Clinical Pharmacy, School of Pharmacy, West Virginia University, Morgantown 26506, USA.
T R
TR
Whetsel
D M
DM
Bell
D000368:Aged; D003331:Coronary Vessels / Q000601:surgery*; D005076:Exanthema / Q000139:chemically induced*; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015607:Stents; D013988:Ticlopidine / Q000009:adverse effects* / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D013988:Ticlopidine